Sp958
OVERVIEW OF STRIDES IN DEI
Date
May 8, 2023
Explore related products in the following collection:
Society: DDW
All symposia are 90-minute sessions, led by two moderators, with a varying number of invited talks. The session may include Q&A which can be included within each speaker’s total presentation time (2-3 minutes at the end) or as a separate block within the session. The session may also include a panel discussion with noted and/or additional speakers. Science type and topic will vary by the session sponsor.
All symposia are 90-minute sessions, led by two moderators, with a varying number of invited talks. The session may include Q&A which can be included within each speaker’s total presentation time (2-3 minutes at the end) or as a separate block within the session. The session may also include a panel discussion with noted and/or additional speakers. Science type and topic will vary by the session sponsor.
Presenter
University of Michigan
Tracks
Related Products
MULTIMODAL SINGLE CELL ANALYSES REVEAL PATHOGENIC FIBROBLASTS IN PERIANAL FISTULA
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
SINGLE-CELL INTESTINAL CHANGES IN PEDIATRIC CROHN'S DISEASE BEFORE AND AFTER ANTI-TNF BLOCKADE.
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
PANEL DISCUSSION
SOCIETY: DDW
IMMUNE EDITING IN THE INVASIVE MARGIN AND NODE DEPOSITS OF COLORECTAL CANCER SELECTS FOR CELLULAR NEIGHBOURHOODS ENRICHED IN PDL1+ CANCER CELLS
BACKGROUND: Perianal fistulae are highly morbid complications of Crohn’s disease (CD) with a cumulative incidence of 20-25%; despite demonstrated efficacy of infliximab treatment, estimates of complete resolution are only 20-30%. Ultimately, 20% of patients will require proctectomy…
